Literature DB >> 7515682

Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors.

T R Burke1, M S Smyth, A Otaka, M Nomizu, P P Roller, G Wolf, R Case, S E Shoelson.   

Abstract

Src homology 2 (SH2) domains participate in protein tyrosine kinase (PTK)-mediated cellular signal transduction through their ability to bind with high affinity to phosphotyrosyl (pTyr)-bearing protein sequences. Although peptides containing pTyr competitively inhibit the binding between phosphoproteins and cognate SH2 proteins in a sequence-specific manner, such peptides are rapidly dephosphorylated by cellular phosphatases. We now describe our efforts to develop SH2 inhibitory peptides containing phosphatase-resistant pTyr surrogates. The parent compound, (phosphonomethyl)phenylalanine (Pmp), is a phosphonate-based mimetic of pTyr in which the phosphate ester oxygen (> COPO3H2) has been replaced by a methylene unit (> CCX2PO3H2, X2 = H2). Pmp analogues bearing fluorine (X2 = H, F or X2 = F2) or hydroxyl (X2 = H, OH) substituents on the phosphonate alpha-methylene carbon have been prepared and incorporated into peptides for use as SH2 domain inhibitors. In an assay using the C-terminal SH2 domain of phosphatidylinositol (PI) 3-kinase, peptides having a GXVPML sequence [where X = pTyr, Pmp, hydroxy-Pmp (HPmp), monofluoro-Pmp (FPmp), and difluoro-Pmp (F2Pmp)] exhibited binding potency in the order HPmp < Pmp < FPmp < F2Pmp = pTyr. Distinct peptide sequences which bind selectively with Src and Grb2 SH2 domains were also prepared with pTyr and F2Pmp. The F2Pmp peptides bound with high (0.2- to 5-fold) relative affinity, compared to analogous pTyr peptides. We conclude that peptides containing F2Pmp bind to SH2 domains with high affinity and specificity and, being resistant to cellular phosphatases, should provide a generally useful tool for disrupting SH2 domain-mediated signaling pathways in intact cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515682     DOI: 10.1021/bi00187a015

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Ligand-receptor binding measured by laser-scanning imaging.

Authors:  P Zuck; Z Lao; S Skwish; J F Glickman; K Yang; J Burbaum; J Inglese
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK.

Authors:  Rong Huang; Hyunju Oh; Allison Arrendale; Victoria A Martin; Jacob Galan; Eric J Workman; Jane R Stout; Claire E Walczak; W Andy Tao; Richard F Borch; Robert L Geahlen
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

3.  A rapid oxime linker-based library approach to identification of bivalent inhibitors of the Yersinia pestis protein-tyrosine phosphatase, YopH.

Authors:  Fa Liu; Ramin Mollaaghababa Hakami; Beverly Dyas; Medhanit Bahta; George T Lountos; David S Waugh; Robert G Ulrich; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2010-03-15       Impact factor: 2.823

4.  Cellular effects of phosphotyrosine-binding domain inhibitors on insulin receptor signaling and trafficking.

Authors:  S Giorgetti-Peraldi; E Ottinger; G Wolf; B Ye; T R Burke; S E Shoelson
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

5.  Oxime-based click chemistry in the development of 3-isoxazolecarboxylic acid containing inhibitors of Yersinia pestis protein tyrosine phosphatase, YopH.

Authors:  Medhanit Bahta; Terrence R Burke
Journal:  ChemMedChem       Date:  2011-06-10       Impact factor: 3.466

Review 6.  Phosphotyrosine isosteres: past, present and future.

Authors:  Robert A Cerulli; Joshua A Kritzer
Journal:  Org Biomol Chem       Date:  2019-11-28       Impact factor: 3.876

7.  Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.

Authors:  Pijus K Mandal; Fengqin Gao; Zhen Lu; Zhiyong Ren; Rajagopal Ramesh; J Sanderson Birtwistle; Kumaralal K Kaluarachchi; Xiaomin Chen; Robert C Bast; Warren S Liao; John S McMurray
Journal:  J Med Chem       Date:  2011-04-26       Impact factor: 7.446

8.  Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors.

Authors:  Robert A Cerulli; Livia Shehaj; Isidora Tosic; Kevin Jiang; Jing Wang; David A Frank; Joshua A Kritzer
Journal:  Bioorg Med Chem       Date:  2020-05-04       Impact factor: 3.641

9.  The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease.

Authors:  M M Harnett; A J Melendez; W Harnett
Journal:  Clin Exp Immunol       Date:  2009-12-01       Impact factor: 4.330

Review 10.  Grb2 signaling in cell motility and cancer.

Authors:  Alessio Giubellino; Terrence R Burke; Donald P Bottaro
Journal:  Expert Opin Ther Targets       Date:  2008-08       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.